Mark Hoffmann, MD
Interventional Cardiology · Wausau, WINPI 1356342034
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $39,136 of the $52,496 with a category attached, or 74.6%. 29 manufacturers reported payments, led by United Therapeutics Corporation at 52.3% of the total. Reporting peaked in 2019 at $22,239 and has fallen 94.7% since, to $1,184 in 2025. Among interventional cardiology clinicians in WI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 153 payments — averaging $343.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$27K
- Bayer$17K
- Heartflow, Inc.$2K
- Actelion Pharmaceuticals US, Inc.$914
- Cvrx, Inc.$633
- AstraZeneca$532
- plus $4K from 23 others
Across 10 payments — averaging $3396.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$26K
- Novartis$4K
- Cvrx, Inc.$4K
What the payments were for
- Speaking & faculty fees$39,13675%
- Travel & lodging$4,4749%
- Food & beverage$8,55516%
- Education$3311%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 54 | $27,481 |
| Bayer | 18 | $17,364 |
| Heartflow, Inc. | 12 | $1,701 |
| Actelion Pharmaceuticals US, Inc. | 11 | $914 |
| Cvrx, Inc. | 2 | $633 |
| AstraZeneca | 5 | $532 |
| Abbott | 7 | $510 |
| Boehringer Ingelheim | 5 | $477 |
| E.r. Squibb & Sons, L.L.C. | 5 | $285 |
| Novartis | 3 | $278 |
| Medtronic(2 entities) | 2 | $221 |
| Daxor Corporation | 2 | $220 |
| Abiomed | 3 | $198 |
| Edwards Lifesciences | 2 | $197 |
| Alnylam Pharmaceuticals Inc. | 2 | $156 |
| Daiichi Sankyo Inc. | 4 | $135 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $132 |
| Lexicon Pharmaceuticals, Inc. | 1 | $125 |
| Pfizer | 2 | $124 |
| Astellas Pharma US Inc | 1 | $115 |
| Inari Medical, Inc. | 2 | $113 |
| Bridgebio Pharma, Inc. | 1 | $108 |
| Amgen | 1 | $100 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $100 |
| Boston Scientific | 1 | $89 |
| Merck | 2 | $81 |
| Inspire Medical Systems, Inc. | 1 | $63 |
| Livanova USA, Inc. | 1 | $25 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$52,496 in reported general payments places this provider in the 90th percentile of 118 interventional cardiology providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 154 | $3,631,231 |
| AdempasRiociguat | 191 | $2,581,494 |
| JardianceEmpagliflozin | 1,114 | $1,170,262 |
| OpsumitMacitentan | 82 | $1,038,913 |
| Tyvaso DpiTreprostinil | 43 | $1,006,955 |
| UptraviSelexipag | 42 | $990,846 |
| VyndaqelTafamidis Meglumine | 34 | $787,722 |
| EntrestoSacubitril/Valsartan | 453 | $523,644 |
| EliquisApixaban | 469 | $505,280 |
| Ambrisentan | 111 | $310,052 |
| MultaqDronedarone Hcl | 112 | $172,510 |
| FarxigaDapagliflozin Propanediol | 175 | $165,282 |
| WinrevairSotatercept-Csrk | 11 | $161,574 |
| CamzyosMavacamten | 20 | $156,200 |
| Orenitram ErTreprostinil Diolamine | 31 | $113,592 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Vyndaqel, Eliquis | $124 | $4,924,233657 claims |
| BayerAdempas, Kerendia | $17,364 | $2,621,425224 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi, Bosentan | $914 | $2,045,857137 claims |
| Boehringer IngelheimJardiance | $477 | $1,170,2621,114 claims |
| NovartisEntresto | $278 | $523,644453 claims |
| AstraZenecaFarxiga | $532 | $165,282175 claims |
| MerckWinrevair | $81 | $161,57411 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $285 | $156,20020 claims |
| AmgenCorlanor | $100 | $29,30324 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 118 interventional cardiology providers in Wisconsin.
Other interventional cardiology in Wausau
- German LarrainWausau$38K
- Marcus SubletteWausau$38K
- Pavel GuigauriWausau$4K
- Michael SalingerMilwaukee$216K
- Arun KalyanasundaramMarshfield$201K
- Michael RosenbergManitowoc$111K
- Tanvir BajwaMilwaukee$106K
- Suhail AllaqabandMilwaukee$88K
- Saif AnwaruddinMilwaukee$80K
- Raaid MuseitifKenosha$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.